Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 52Active not recruiting 5Withdrawn 2Recruiting 2Unknown 1Terminated 1No longer available 1

Sponsor Class

OTHER 79INDUSTRY 8NIH 5NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 18Prostatic Neoplasms 15Neoplasms 12Multiple Myeloma 11Carcinoma, Non-Small-Cell Lung 11Melanoma 9Pancreatic Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Colorectal Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Sarcoma 4Ovarian Neoplasms 4Osteosarcoma 4Hematologic Neoplasms 4Brain Neoplasms 4Teratoma 3Smoldering Multiple Myeloma 3Small Cell Lung Carcinoma 3Recurrence 3Neoplasms, Germ Cell and Embryonal 3Neoplasm Metastasis 3Malignant Solid Neoplasm 3HIV Infections 3Fallopian Tube Neoplasms 3Colonic Neoplasms 3

Interventions

Specimen Handling 2sargramostim 1lorlatinib 1etoposide phosphate 1dinutuximab 1X-Rays 1Vincristine 1Topotecan 1Thiotepa 1Stem Cell Transplantation 1Razoxane 1Radiation 1Platinum 1Phantoms, Imaging 1Melphalan 1Magnetic Resonance Spectroscopy 1Isotretinoin 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Congresses as Topic 1Colony-Stimulating Factors 1Cisplatin 1Carboplatin 1Busulfan 1Bone Density 1Biopsy 1Absorptiometry, Photon 13-Iodobenzylguanidine 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × NETWORK × Neuroblastoma × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡